AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27487342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 24072523 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive support groups
Number of subjects: 254
Study 24072523 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 254
Study 22189004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling during 10 home visits
Number of subjects: 397
Study 22189004 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 397
Study 22189004 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding up to 6 months
Number of subjects: 397
Study 20569506 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet rich in SFA
Number of subjects: 417
Study 20569506 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet rich in MUFA
Number of subjects: 417
Study 20569506 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high-complex carbohydrate diet with n-3 supplementation (LFHCC n-3)
Number of subjects: 417
Study 20569506 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high-complex carbohydrate diet without n-3 supplementation (LFHCC)
Number of subjects: 417
Study 20569506 — intervention group
Group type: COMPARATOR
Intervention: All diets
Number of subjects: 417
Study 18477897 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intra-arterial hepatic fotemustine
Number of subjects: 22
Study 18477897 — intervention group
Group type: COMPARATOR
Intervention: Control group (3:1 matched control group)
Number of subjects: 22
Study 16006842 — intervention group
Group type: EXPERIMENTAL
Intervention: Acticoat
Number of subjects: 47
Study 16006842 — intervention group
Group type: COMPARATOR
Intervention: silver sulfadiazine (AgSD)
Number of subjects: 47
Study 12544993 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligon-treated catheter (polyurethane combined with silver, carbon, and platinum)
Number of subjects: 545
Study 12544993 — intervention group
Group type: COMPARATOR
Intervention: Conventional benzalkonium-treated double-lumen central venous catheter
Number of subjects: 545
Study 10738092 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV
Number of subjects: 123
Study 10738092 — intervention group
Group type: COMPARATOR
Intervention: PN23
Number of subjects: 123
Study 8651107 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone alone
Number of subjects: 0
Study 8651107 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone with testolactone
Number of subjects: 0
Study 1725153 — intervention group
Group type: EXPERIMENTAL
Intervention: 400mg aqueous solution
Number of subjects: 24
Study 1725153 — intervention group
Group type: COMPARATOR
Intervention: 400mg tablet
Number of subjects: 24
Study 1725153 — intervention group
Group type: COMPARATOR
Intervention: 2 x 200mg tablets
Number of subjects: 24
Study 6178151 — intervention group
Group type: EXPERIMENTAL
Intervention: Hapten (10 or 20 ml) before dextran infusion
Number of subjects: 3887
Study 6178151 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70 without hapten
Number of subjects: 3887
Study 30514803 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg
Number of subjects: 422
Study 30514803 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 800 mg
Number of subjects: 422
Study 30146644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilted dental implantation
Number of subjects: 80
Study 30146644 — intervention group
Group type: COMPARATOR
Intervention: Maxillary sinus lifting
Number of subjects: 80
Study 27532829 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid 5-10 mg
Number of subjects: 216
Study 27532829 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid 10 mg
Number of subjects: 216
Study 27532829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 25418218 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant BNP (rhBNP; 0.005 μg/kg/min)
Number of subjects: 1000
Study 25418218 — intervention group
Group type: COMPARATOR
Intervention: Isotonic normal saline (NaCl 0.9%, 1 mL/kg/h) for 24 hours before CA or PCI
Number of subjects: 1000
Study 22854549 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-focused prenatal program
Number of subjects: 46
Study 22854549 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 20635771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) for Panic Disorder
Number of subjects: 0
Study 18192953 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuretic peptides (NPs) applied prophylactically, in lower doses, for prolonged duration.
Number of subjects: 0
Study 18192953 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuretic peptides (NPs)
Number of subjects: 0
Study 15293053 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE group (PG)
Number of subjects: 35
Study 15293053 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 35
Study 12239065 — intervention group
Group type: EXPERIMENTAL
Intervention: STI‐571 (Gleevec, imatinib mesylate)
Number of subjects: 0
Study 8084629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal hinge techniques
Number of subjects: 100
Study 8084629 — intervention group
Group type: COMPARATOR
Intervention: Other lateral crural techniques
Number of subjects: 100
Study 2913779 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 69
Study 2913779 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 69
Study 2913779 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 69
Study 2913779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 2913779 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin, Propranolol, Hydrochlorothiazide (all drug treatment groups)
Number of subjects: 69
Study 2913779 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Hydrochlorothiazide
Number of subjects: 69
Study 2913779 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatment groups
Number of subjects: 69
Study 64267 — intervention group
Group type: EXPERIMENTAL
Intervention: gestonorone caproate (200 mg daily and 200 mg on alternate days)
Number of subjects: 18
Study 64267 — intervention group
Group type: EXPERIMENTAL
Intervention: cyproterone acetate (300 mg daily)
Number of subjects: 18
Study 64267 — intervention group
Group type: EXPERIMENTAL
Intervention: gestonorone caproate on alternate days
Number of subjects: 18
Study 64267 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 31952493 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TDM (therapeutic drug monitoring) of beta-lactam and fluoroquinolones
Number of subjects: 450
Study 31952493 — intervention group
Group type: COMPARATOR
Intervention: Non-TDM (control group)
Number of subjects: 450
Study 31179489 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearic acid diet
Number of subjects: 20
Study 31179489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid diet
Number of subjects: 20
Study 31179489 — intervention group
Group type: COMPARATOR
Intervention: Palmitic acid diet
Number of subjects: 20
Study 28765006 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Relapse Prevention (MBRP)
Number of subjects: 0
Study 28765006 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26350273 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg once daily for 12 days
Number of subjects: 24
Study 26350273 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 days
Number of subjects: 24
Study 23032917 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 47
Study 23032917 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 47
Study 22254683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking training group
Number of subjects: 16
Study 22254683 — intervention group
Group type: COMPARATOR
Intervention: Move group
Number of subjects: 16
Study 17392700 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-median consumption of sherry and port among individuals with a prior skin cancer history
Number of subjects: 1360
Study 17392700 — intervention group
Group type: COMPARATOR
Intervention: Total alcohol intake, beer, white wine, red wine, sherry, and port
Number of subjects: 1360
Study 16447002 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 156
Study 16447002 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 156
Study 12952402 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants interacting with an adult who expressed excitement about a new toy.
Number of subjects: 0
Study 10708180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg)
Number of subjects: 10
Study 10708180 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg)
Number of subjects: 10
Study 10708180 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 10
Study 10708180 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mL of sterile water)
Number of subjects: 10
Study 15096005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous therapy with continuous IGF‐I (0.01 mg/kg/hour)
Number of subjects: 33
Study 15096005 — intervention group
Group type: COMPARATOR
Intervention: Standard neurosurgical intensive care plus aggressive nutritional support (Control)
Number of subjects: 33
Study 8455310 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lipid emulsion with a PL/TG weight ratio of 0.12 (group A)
Number of subjects: 18
Study 8455310 — intervention group
Group type: COMPARATOR
Intervention: 10% emulsion with a PL/TG weight ratio of 0.06 (group B)
Number of subjects: 18
Study 8455310 — intervention group
Group type: COMPARATOR
Intervention: 20% emulsion with a PL/TG weight ratio of 0.06 (group C)
Number of subjects: 18
Study 3786302 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic analog of leu-enkephalin (dalargin)
Number of subjects: 40
Study 3786302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30012385 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonols (63.36 mg/d)
Number of subjects: 340
Study 30012385 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanols (107.61 mg/d)
Number of subjects: 340
Study 30012385 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanones (40.92 mg/d)
Number of subjects: 340
Study 30012385 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechins (63.36 mg/d)
Number of subjects: 340
Study 30012385 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonols and catechins
Number of subjects: 340
Study 30012385 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanones
Number of subjects: 340
Study 26970526 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib XR 11 mg QD
Number of subjects: 24
Study 26970526 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib IR 5 mg twice daily
Number of subjects: 24
Study 26970526 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib XR 11 mg QD (fed state)
Number of subjects: 24
Study 26970526 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib XR 11 mg QD (multiple doses)
Number of subjects: 24
Study 26970526 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib IR 5 mg twice daily (multiple doses)
Number of subjects: 24
Study 24828848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dezocine 0.1 mg/kg
Number of subjects: 80
Study 24828848 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (0.9% saline)
Number of subjects: 80
Study 22092380 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (CM)
Number of subjects: 24
Study 22092380 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue autograft (CTG)
Number of subjects: 24
Study 20194448 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab retreatment (2 x 1000 mg IV)
Number of subjects: 559
Study 20194448 — intervention group
Group type: COMPARATOR
Intervention: Placebo retreatment
Number of subjects: 559
Study 20194448 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab retreatment
Number of subjects: 559
Study 18611254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR)
Number of subjects: 31
Study 18611254 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic echocardiogram (TTE)
Number of subjects: 31
Study 15867994 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 210
Study 15867994 — intervention group
Group type: COMPARATOR
Intervention: Transluminal coronary angioplasty (TCA)
Number of subjects: 210
Study 12740233 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (200 to 300 mg/d) for 1 to 3 weeks
Number of subjects: 0
Study 12740233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11108563 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 0
Study 11108563 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0
Study 11108563 — intervention group
Group type: EXPERIMENTAL
Intervention: TUMT
Number of subjects: 0
Study 11108563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost evaluation
Number of subjects: 0
Study 8839577 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally acceptable cervical cancer screening program using Talking Circles
Number of subjects: 400
Study 8839577 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 400
Study 1624634 — intervention group
Group type: EXPERIMENTAL
Intervention: h-EGF (10 micrograms/mL, applied topically twice a day for up to 10 weeks)
Number of subjects: 44
Study 1624634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (applied topically twice a day for up to 10 weeks)
Number of subjects: 44
Study 1624634 — intervention group
Group type: EXPERIMENTAL
Intervention: h-EGF
Number of subjects: 44
Study 1624634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 6334524 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (mean dose 0.4 micrograms/day)
Number of subjects: 23
Study 6334524 — intervention group
Group type: COMPARATOR
Intervention: Calcium and placebo
Number of subjects: 23
Study 29372470 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat (40 to 160 mg/day, administered BID for 28 weeks)
Number of subjects: 65
Study 29372470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo administered BID for 28 weeks)
Number of subjects: 65
Study 27863179 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline (24 weeks treatment)
Number of subjects: 335
Study 25358679 — intervention group
Group type: COMPARATOR
Intervention: Antenatal milk expressing starting at 36 weeks gestation, encouraged to express twice daily for 10 min.
Number of subjects: 658
Study 25358679 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 658
Study 25358679 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal milk expressing intervention.
Number of subjects: 658
Study 22873719 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional intelligence training (12 sessions)
Number of subjects: 30
Study 22873719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no emotional intelligence training)
Number of subjects: 30
Study 19896655 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid from patients with endometriosis
Number of subjects: 38
Study 19896655 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal fluid from nonendometriosis patients (control)
Number of subjects: 38
Study 19896655 — intervention group
Group type: COMPARATOR
Intervention: Human tubal fluid (HTF) media
Number of subjects: 38
Study 19227901 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 3 months
Number of subjects: 165
Study 19227901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no inhibitors of GMG-CoA-reductase)
Number of subjects: 165
Study 15895898 — intervention group
Group type: EXPERIMENTAL
Intervention: SINGLE therapy (initially sulfasalazine with or without prednisolone)
Number of subjects: 157
Study 15895898 — intervention group
Group type: COMPARATOR
Intervention: COMBI therapy (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Number of subjects: 157
Study 15895898 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL‐2R <442 U/ml
Number of subjects: 157
Study 15895898 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL‐2R level
Number of subjects: 157
Study 12195121 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 20
Study 12195121 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 20
Study 12195121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11233145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba leaf extract (GBLE)
Number of subjects: 0
Study 7598110 — intervention group
Group type: EXPERIMENTAL
Intervention: FR-4 appliance and lip-seal training
Number of subjects: 40
Study 7598110 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 2205128 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg naltrexone
Number of subjects: 35
Study 2205128 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg naltrexone
Number of subjects: 35
Study 2205128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 433996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent clamping regimen (started on the first postoperative day)
Number of subjects: 87
Study 433996 — intervention group
Group type: COMPARATOR
Intervention: Constant open drainage
Number of subjects: 87
Study 29921504 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (90 trials of three balance tasks)
Number of subjects: 32
Study 29921504 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with high lower limb power
Number of subjects: 32
Study 29921504 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with low lower limb power
Number of subjects: 32
Study 29921504 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prior practice)
Number of subjects: 32
Study 28034612 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 152
Study 28034612 — intervention group
Group type: EXPERIMENTAL
Intervention: Information page intervention
Number of subjects: 152
Study 28034612 — intervention group
Group type: COMPARATOR
Intervention: Video control
Number of subjects: 152
Study 28034612 — intervention group
Group type: COMPARATOR
Intervention: Information page control
Number of subjects: 152
Study 25893514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015%
Number of subjects: 40
Study 25893514 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% + benzalkonium chloride 0.02%
Number of subjects: 40
Study 23727387 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (1.5 mg)
Number of subjects: 105
Study 23727387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 21820539 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly musculoskeletal treatment for 6 weeks in addition to normal optimal physiotherapy care
Number of subjects: 20
Study 21820539 — intervention group
Group type: COMPARATOR
Intervention: Normal optimal physiotherapy care
Number of subjects: 20
Study 19304565 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minutes of chest percussion at noon
Number of subjects: 28
Study 19304565 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chest percussion)
Number of subjects: 28
Study 17077730 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 21
Study 17077730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15095516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led diabetes management program with low-literacy-oriented interventions
Number of subjects: 159
Study 15095516 — intervention group
Group type: EXPERIMENTAL
Intervention: Low literacy patients
Number of subjects: 159
Study 15095516 — intervention group
Group type: EXPERIMENTAL
Intervention: High literacy patients
Number of subjects: 159
Study 11573528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.5 mg kg(‐1) at induction followed by continuous infusion of 3 mg kg(‐1) over 24 h (pre ketoprofen group)
Number of subjects: 106
Study 11573528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.5 mg kg(‐1) after surgery followed by continuous infusion of 3 mg kg(‐1) over 24 h (post ketoprofen group)
Number of subjects: 106
Study 11573528 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo group)
Number of subjects: 106
Study 9661740 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of carbamazepine (CBZ)
Number of subjects: 3
Study 9661740 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/day of valproic acid (VPA)
Number of subjects: 3
Study 9661740 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of carbamazepine (CBZ) and 800 mg/day of valproic acid (VPA)
Number of subjects: 3
Study 8151854 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam treatment (40 L/min of heated saturated air at 43 degrees C for 60 minutes)
Number of subjects: 68
Study 8151854 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (2 L/min of ambient air at 20 degrees C to 24 degrees C)
Number of subjects: 68
Study 3219316 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g/kg body-weight per day
Number of subjects: 15
Study 3219316 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 g/kg body-weight per day
Number of subjects: 15
Study 3219316 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg body-weight per day
Number of subjects: 15
Study 3219316 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 g/kg body-weight per day
Number of subjects: 15